Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease

Gut

Volumn 47, Issue 1, 2000, Pages 63-73

  Von Lampe, B ^a   Barthel, B ^a   Riecken, E O ^a   Coupland, S E ^a   Rosewicz, S ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Crohn's disease; Extracellular matrix; Matrix metalloproteinases; Polymerase chain reaction; Ulcerative colitis

Indexed keywords

COLLAGENASE; GELATINASE A; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; COLON BIOPSY; COLON CROHN DISEASE; COLON MUCOSA; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; ULCERATIVE COLITIS;

EID: 0033933804     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.1.63     Document Type: Article

References (54)

1. Podolsky DK. Healing the epithelium: solving the problem from two sides. J Gastrocntcrol 1997;32:122-6.
2. Kovacs EJ, DiPietro LA. Fibrogenic cytokines and connective tissue production. FASEBJ 1994;8:854-61.
3. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity'. J Immunol 1996;156:1-1.
4. Dunsmore SE, Saarialho-Kere UK, Roby JD, et al. Matrilysin expression and function in airway epithelium. J Clin Iiiz-cst 1998;102:1321-31.
5. Pilcher BK, Dumin JA, Sudbeck BD, et ai. The activity of collagenase-l is required for keratinocyte migration on a type I collagen matrix. J Cell Dial 1997;137:1445-57.
6. Hiraoka N, Alien E, Apel IJ, et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998;95:365-77.
7. Gailit J, Clark RA. VC'ound repair in the context of extracellular matrix. CurrOpin CellBiol 1994;6:717-25.
8. Baragi VM, Qiu L, Gunja-Smith Z, et al. Role of metalloproteinases in the development and healing of acetic acid-induced gastric ulcer in rats. ScandJ Gasiroenterol 1997;32:419-26.
9. Arthur MJ. Fibrosis and altered matrix degradation. Digestion 1998;59:376-80.
10. Brovn PD. Matrix metalloproteiriases in gastrointestinal cancer. Gut 1998;43:161-3.
11. Massova I, Kotra LP, Fridman R, el al. Matrix metalloproteinases: structures, evolution, and diversification. FASEBJ 1998;12:1075-95.
12. Voessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEBJ 1991;5:214554.
13. Krane SM. Clinical importance of metalloproteinases and their inhibitors. Ann N YAcad Sei 1994;732:1-10.
14. Himelstein BP, Canete-Soler R, Bernhard EJ, et al Metalloproteinases in tumor progression: the contribution of MMP-9. Im-asion Metastasis 1994;14:246-58.
15. Ohuchi E, Imai K, Fujii Y, et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Client 1997; 272:2446-51.
16. Sato H, Seiki Ai. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. JBiochcm (Tokyo) 1996; ' 119:209-15.
17. Nagase H. Activation mechanisms of matrix metalloproteinases. BiolChem 1997;37S:151-60.
18. Ueno H, Nakamura H, Inoue M, et al. Expression and tissue localization of membrane-types 1,2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997;57:2055-60.
19. Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. EurJ Cell Biol 1997;74:111-22.
20. Alexander-Williams J. Surgical aspects of inflammatory bowel disease. 1990;172:39-42.
21. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992;33:938~41.
22. Jung K, Lein M, Ulbrich N, et al. Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects. Prosrate 1998;34: 130-6.
23. MacNaul KL, Chartrain N, Lark M, et al. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-l and tumor necrosis factor-alpha on stromelysin expression. BMJ 1990;301:828.
24. Kohn EC, Jacobs V, Kim YS, et al. Calcium influx modulates expression of matrix metalloproteinase-2 (72kDa type IV collagenase, gelatinase A). J Biol Chem 1994; 269:21505-11.
25. Graham MF, Villey A, Zhu YN, et al. Corticosteroids repress the interleukin 1 beta-induced secretion of collagenase in human intestinal smooth muscle cells. Gastrocnterology 1997;! 13:1924-9.
26. Jin CF, Mata M, Fink DJ. Rapid construction of deleted DNA fragments for use as internal standards in competitive PCR. FCR Methods Appl 1994;3:252-5.
27. Cordell JL, Falini B, Erber VN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes). J Histochem Cytoclicm 1984;32:219-29.
28. Hsu SM, Raine L, Fanger HJ. Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. JHistocliem Cyaxhem 1981;29: 577-80.
29. Truelove SC, Richards VC. Biopsie studies in ulcerative colitis. BMJ 1956;3:1315-18.
30. Lohi J, Keski-Oja J. Calcium ionophores decrease pericellular gelatinolytic activity via inhibition of 92-kDa gelatinase expression and decrease of 72-kDa gelatinase activation. J BiolChem 1995;270:17602-9.
31. Vang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 1998;S3:832-40.
32. Alatthes H, Herbst H, Schuppan D, et al. Cellular localization of procollagen gene transcripts in inflammatory bowel diseases. Gastrocmcrology 1992;102:431-42.
33. Ohtani H, Nagai T, Nagura H. Similarities of in situ mRNA expression between gelatinase A (MMP-2) and type I procollagen in human gastrointestinal carcinoma: comparison with granulation tissue reaction. Jpn J Cancer Res 1995;86: 833-9.
34. Okada A, Tomasetto C, Lutz Y, et al. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J Cell Dial 1997;137: 67-77.
35. Theret N, Musso O, A LHh, et al. Differential expression and origin of membrane-type 1 and 2 matrix metalloproteinases (MT-MMPs) in association with MMP2 activation in injured human ivers.AmJPathol 1998;153:945-54.
36. Ohtani H. Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/ inflammatory reactions. Pathol lut 1998;4S:l-9.
37. Stetler-Stevenson VG, Brown PD, Onisto M, et al. Tissue inhibitor of metalIoproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. FEES Lett 1990;269:93-5.
38. Shapiro SD, Kobayashi DK, Vi'elgus HG. Identification of TIMP-2 in human alveolar macrophages. Regulation of biosynthesis is opposite to that of metalloproteinases and TIMP-1. J Bio! Chem 1992;267:13890-4.
39. Hammani K, Blakis A, Morsette D, el al. Structure and characterization of the human tissue " inhibitor of metalloproteinases-2 gene. J Biol Chem 1996;271:25498505.
40. Bailey CJ, Hembry RM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. JC/mRjr/io/1994;47:113-16.
41. Matthes H, Stallmach A, Matthes B, et al. Indications for different collagen metabolism in Crohn disease and ulcerative colitis. fled Klin 1993;SS:185-92.
42. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, et al. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996; 148:519-26.
43. Velgus HG, Senior RM, Parks VC, et al. Neutral proteinase expression by human mononuclear phagocytes: a prominent role of cellular differentiation. Matrix Supp! 1992;!: 363-7.
44. Lacraz S, Isler P, Vey E, et al. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994;269: 22027-33.
45. Pender SL, Breese EJ, Günther U, et al. Suppression of T cell-mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroaitewlogy 1998;! 15:57383.
46. Daum S, Bauer U, Foss HD, et al. Increased expression of mRNA for matrix metalloproteinases-1 and -3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease. Gut 1999;44:1725.
47. Campbell EJ, Cury JD, Shapiro SD, et al. Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J Biol Chem 1991 ;266:3893-9.
48. Pender SL, Tickle SP, Docherty AJ, et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immimol 1997;15S:1582-90.
49. Otani Y, Sakurai Y, Kameyama K, et al. Matrix metalloproteinase gene expression in chronic gastric ulcer: a potential role of eosinophils in perforation. J Clin Gastrocntcrol 1997; 25:101-4.
50. Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIA1P expression in chronic ulcers. Arch Dermatol Res 1998;290:S47-54.
51. Vassalli JD, Saurat JH. Cuts and scrapes? Plasmin heals! Nat Med 1996;2:284-5.
52. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Distinct expression profiles of stromelysin-2 (MMP10), colIagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcérations. Am J Pathol 1998;152: 1005-14.
53. Gordon JL, Drummond AH, Galloway VA. Metalloproteinase inhibitors as therapeutics. Clin Exp Rhewnatol 1993;11:91-1.
54. Ryan ME, Ramamurthy S, Golub LM. Matrix metalloproteinases and their inhibition in periodontal treatment. Cttrr Opin Pcriodomol 1996;3:85-96.